Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

Abbott Laboratories recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

On Thursday, analysts from Oppenheimer gave the company an “outperform” rating and a price target of $134, a 2-percent upside ...

Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $158.00.

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...